REC 0545, Recordati’s investigational treatment for maple syrup urine disease (MSUD), a rare genetic metabolic disorder that starts in early infancy, is among the latest products that the European Medicines Agency has begun reviewing for potential pan-EU marketing authorization.
MSUD, which gets its name from the distinctive sweet odor of urine in infants with the condition, is a disease...






